INTEGRATED BIOPHARMA INC

Integrated BioPharma reported a significant decline in its financial results for the quarter and nine-month period ended March 31, 2026. Quarterly revenue decreased by 27.3% to $10.1 million, leading to an operating loss of $1.1 million and a net loss of $0.8 million. For the nine-month period, revenue fell by 15.2% to $34.1 million, resulting in a net loss of $1.5 million. Management attributed the revenue decrease primarily to reduced sales from its two largest customers in the Contract Manufacturing Segment.

Integrated BioPharma Inc. reported a significant decline in its financial performance for the three months ended March 31, 2026, with net sales decreasing by 27.5% to $10.1 million and a net loss of $(837) thousand, compared to a net income of $611 thousand in the prior year. The company also experienced a gross loss and operating loss for the quarter. Despite the losses, cash increased to $5.8 million, and net cash from operating activities for the nine months improved. The company highlighted risks from major customer concentration and negative impacts on margins from inflation and tariffs.

Integrated BioPharma Inc. and its wholly-owned subsidiary, Manhattan Drug Company, Inc., announced an extension of their Line of Credit with PNC Bank, National Association. The expiration date for the credit facility has been moved from April 15, 2026, to July 14, 2026. This extension, effective April 16, 2026, provides the company with continued access to its credit facility for an additional three months, offering short-term financial flexibility.